Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Variable progression of HIV-associated dementia

F H Bouwman1, R L Skolasky, D Hes

  • 1Johns Hopkins University, Department of Neurology, Baltimore, MD, USA.

Neurology
|June 20, 1998
PubMed
Summary

HIV-associated dementia (HAD) progression varies significantly. Injection drug use and psychomotor slowing predict faster neurologic decline, linked to increased central nervous system macrophage activation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlates.

Alzheimer's research & therapy·2025
Same author

How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment - a bidding game experiment.

Alzheimer's research & therapy·2023
Same author

High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study.

Alzheimer's research & therapy·2019
Same author

Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.

Molecular neurobiology·2018
Same author

7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests.

AJNR. American journal of neuroradiology·2018
Same author

[Doctor, is my mother suffering from dementia?]

Nederlands tijdschrift voor geneeskunde·2017

Area of Science:

  • Neuroscience
  • Immunology
  • Infectious Diseases

Background:

  • HIV-associated dementia (HAD) presents a significant neurological challenge.
  • Understanding the clinical course and progression markers of HAD is crucial for patient management.

Purpose of the Study:

  • To characterize the clinical course of HIV-associated dementia (HAD).
  • To identify predictive markers for rapid neurologic progression in HAD patients.

Main Methods:

  • Studied 71 patients diagnosed with HAD between 1984-1994.
  • Assessed neurologic progression using the MSK dementia severity score.
  • Examined autopsy material for macrophage activation markers (HAM56) and gp41 in 30 individuals.

Main Results:

Related Experiment Videos

  • Median survival was 3.3 months for rapid progression and 6.1 months for no progression.
  • Rapid progression associated with injection drug use, lower CD4+ counts, and psychomotor slowing.
  • Less macrophage activation in the CNS was observed in patients with slower progression.

Conclusions:

  • Neurologic progression and survival in HAD are highly variable.
  • Injection drug use and psychomotor slowing are predictors of rapid neurologic progression.
  • Increased CNS macrophage activation correlates with more rapid HAD progression.